FDG-PET引导下择区放疗降级可降低头颈癌模型化晚期吞咽相关毒性
该研究在26例头颈癌患者中进行了个体内计划比较,对比FDG-PET引导的缩小择区淋巴结照射(RNI)和累及淋巴结照射(INI)与标准择区淋巴结照射(ENI)的预测毒性。结果显示RNI和INI均降低了模型化吞咽困难、喂养管依赖和口干的风险,其中INI降幅更大,且在下咽癌和喉癌中预测获益最大。
要点
- FDG-PET引导的体积降级策略可降低模型化晚期吞咽相关毒性。
- INI较RNI带来更大的吞咽困难和口干风险降幅。
- 下咽癌和喉癌患者的预测获益最大。
核心结论
- FDG-PET引导的体积降级与更低的模型化晚期吞咽相关毒性相关,支持开展相关临床试验。
研究设计与样本
- 个体内计划比较研究,共26例患者,比较RNI、INI与ENI的预测毒性。
- RNI将择区体积限制在肉眼病变上下2 cm范围内,INI省略择区治疗。
- 在代表性口咽癌病例中创建了质子计划。
主要发现
- 中位总PTV从ENI的540 cm3降至RNI的418 cm3和INI的173 cm3。
- RNI和INI分别降低模型化吞咽困难风险5.9个百分点(95%CI 2.3–9.6 pp;padj=0.005)和11.0个百分点(6.9–15.2 pp;padj<0.001)。
- RNI和INI分别降低喂养管依赖风险2.8个百分点(1.2–4.5 pp;padj=0.005)和4.2个百分点(2.5–6.0 pp;padj<0.001)。
- RNI和INI分别降低口干风险2.8个百分点(0.0–5.7 pp;padj=0.054)和8.8个百分点(5.5–12.2 pp;padj<0.001)。
- 预测获益在下咽癌和喉癌中最大,部分病例中降级质子治疗进一步降低危及器官剂量。
关键数值与推荐
- 共主要终点为6个月吞咽困难、喂养管依赖和口干的正常组织并发症概率(NTCP)。
临床怎么用
- FDG-PET引导的体积降级策略可用于筛选适合降低晚期吞咽相关毒性的头颈癌患者。
- 下咽癌和喉癌可能是体积降级策略的优先人群。
局限性
- 研究为模型化计划比较,非临床结局观察。
- 样本量较小(n=26),质子计划仅在代表性口咽癌病例中创建。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Whether FDG-PET-guided de-escalation of elective target volumes in radiotherapy of the head and neck reduces late toxicity remains uncertain. Therefore, we compared predicted toxicity of two de-escalation strategies-reduced elective nodal irradiation (RNI) and involved node irradiation (INI)-with standard elective nodal irradiation (ENI). MATERIALS AND METHODS: In a within-patient plan comparison (n = 26), we generated RNI and INI plans using the same FDG-PET informed high-/intermediate-risk targets as ENI. RNI limited elective volumes to within 2 cm cranio-caudal from gross disease; INI omitted elective treatment. Proton plans were created in representative oropharyngeal cases. Co-primary outcomes were six-month normal-tissue complication probabilities (NTCPs) for dysphagia, feeding-tube dependence, and xerostomia. RESULTS: Median total planning target volume decreased from 540 cm3 (ENI) to 418 cm3 (RNI) and 173 cm3 (INI). RNI and INI reduced modeled dysphagia risk by 5.9 percentage points (pp) (95% CI 2.3 to 9.6 pp; padj = 0.005) and 11.0 pp (6.9 to 15.2 pp; padj < 0.001), feeding-tube dependence by 2.8 pp (1.2 to 4.5 pp; padj = 0.005) and 4.2 pp (2.5 to 6.0 pp; padj < 0.001), and xerostomia by 2.8 pp (0.0 to 5.7 pp; padj = 0.054) and 8.8 pp (5.5 to 12.2 pp; padj < 0.001), respectively. Predicted benefits were greatest in hypopharyngeal and laryngeal cancers. In selected cases, de-escalated proton therapy further reduced organ-at-risk dose. CONCLUSIONS: FDG-PET-guided volumetric de-escalation was associated with lower modeled late swallowing-related toxicity. These findings support the rationale for ongoing and future trials investigating volumetric de-escalation strategies.
引用
- Stritzke F, Dvornikovich K, Lau H, et al. De-escalation of elective radiotherapy guided by FDG-PET lowers modeled late swallowing-related toxicity in head and neck cancer. Clin Transl Radiat Oncol. 2026. PMID: 42016183. doi:10.1016/j.ctro.2026.101156
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。